Quest Diagnostics (DGX) Director Lassiter Wright III Buys 6 Shares

What Happened
Lassiter Wright III, a director of Quest Diagnostics (DGX), acquired 6 shares of Quest Diagnostics common stock on July 22, 2026, at $206.81 per share for a total of $1,241. This was a purchase (acquisition) and appears to be a routine reinvestment of dividends rather than a market open‑market buy.

Key Details

• Transaction date: 2026-07-22; reported on Form 4 filed 2026-07-27 (accession 0001022079-26-000080).
• Price: $206.81 per share; Shares acquired: 6; Total value ≈ $1,241.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Filing note: Transaction marked with "L" (late) on the Form 4, but the filing discloses the shares were purchased via a dividend reinvestment plan.
• Footnote: The shares were acquired under a broker‑administered dividend reinvestment plan and were eligible for deferred reporting on Form 5 under Rule 16a‑6; the reporting person elected to report the transaction early on this Form 4.

Context
Dividend reinvestment purchases are common, small, and generally considered routine rather than strong signals of insider conviction. The late‑mark on the Form 4 is explained by the transaction’s eligibility for deferred reporting under Rule 16a‑6; the director opted to report it on Form 4 anyway.